Stable Micronized Vaccines Against Smallpox and Japanese Encephalitis

针对天花和日本脑炎的稳定微粉化疫苗

• 批准号: 7487890
• 负责人: Victor Bronshtein
• 金额: $ 44.6万
• 依托单位: UNIVERSAL STABILIZATION TECHNOLOGIES
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-08-15 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7487890
• 关键词: Agreement; American; Animal Model; Animals; Anthrax disease; Antibiotics; Antibodies; Antibody Formation; Antidotes; Antitoxins; Antiviral Agents; Applications Grants; Area; Asia; Attention; Attenuated; Attenuated Live Virus Vaccine; Attenuated Vaccines; Australia; Bacteria; Biological; Biological Assay; Biological Preservation; Biological Warfare; Bioterrorism; Bovine Spongiform Encephalopathy; Breathing; Capsid Proteins; Case Fatality Rates; Case Study; Categories; Cells; Chemicals; Chick Embryo; Child; ChimeriVax; Clinical; Cold Chains; Collaborations; Complex; Condition; Contracts; Cost Savings; Country; Cowpox virus; Culicidae; Cytotoxic T-Lymphocytes; Developing Countries; Development; Disease; Dose; Drug Formulations; Ectromelia; Effectiveness; Emergency Situation; Encephalitis; Endemic Diseases; Engineering; Ensure; Epidemic; Excision; Fibroblasts; Flavivirus; Fluorocarbons; Freeze Drying; Freezing; Genes; Genomics; Glycoproteins; Goals; Government; Health Professional; High temperature of physical object; Host Defense; Human; Immune response; Immunity; Immunization; Immunodeficient Mouse; In Vitro; Incidence; Infection; Injectable; Injection of therapeutic agent; Intramuscular; Intraperitoneal Injections; Japanese Encephalitis; Japanese Encephalitis Vaccines; Licensing; Life; Liquid substance; Logistics; Measures; Methods; Modified Vaccinia Virus Ankara; Monkeypox; Morbidity - disease rate; Mus; National Institute of Allergy and Infectious Disease; Needles; Neomycin; Neonatal; Neurologic; Nose; Oils; Oral; Orthopoxvirus; PTPN11 gene; Particle Size; Personal Satisfaction; Persons; Pharmaceutical Preparations; Phase I Clinical Trials; Phase II Clinical Trials; Phase III Clinical Trials; Poxviridae; Preparation; Prevention; Preventive; Principal Investigator; Process; Production; Protocols documentation; RNA; RNA Viruses; Range; Rate; Refrigeration; Research Personnel; Resources; Route; Safety; Saline; Seeds; Serial Passage; Shipping; Ships; Smallpox; Smallpox Vaccine; Smallpox Viruses; Solutions; Standards of Weights and Measures; Sterility; Structural Protein; Subcutaneous Injections; Survivors; System; Technology; Temperature; Terrorism; Testing; Therapeutic; Tick-Borne Encephalitis; Time; Today; Toxin; Transportation; Tularemia; United States Food and Drug Administration; United States National Institutes of Health; Vaccination; Vaccine Production; Vaccines; Vaccinia; Vaccinia virus; Vial device; Viral Proteins; Virus; Virus Replication; Water; Week; West Nile virus; Work; Yellow Fever; biodefense; cold temperature; cost; day; design; immunogenic; immunogenicity; indicated prevention; lot production; member; mortality; mouse model; nervous system disorder; neutralizing antibody; new technology; novel strategies; novel vaccines; pathogen; programs; psychologic; reconstitution; research study; response; theories; tissue culture; tool; vaccine efficacy; vaccine evaluation; vaporization; vector control; vector vaccine

DESCRIPTION (provided by applicant): Smallpox was one of the most important causes of morbidity and mortality worldwide through the first half of the 20th Century. Smallpox is a potential agent of bioterrorism; it has been designated as Category A Priority Pathogen. Despite the declaration of smallpox eradication in 1980, the existence of variola stockpiles and the threat of bioterrorism demand that immunity to smallpox through vaccination be maintained. In recent years, mosquito-borne infections are reemerging or emerging worldwide at an alarming rate. Japanese Encephalitis is a potential agent of bioterrorism; it has been designated as Category C Priority Pathogen. There are no licensed antiviral drugs against JE and only experimental treatments exist for smallpox. Therefore, vaccination and vector control are the only effective preventive tools, with vaccination being the most cost-effective strategy. Because of this effective protection of people requires immediate application of the countermeasures against these pathogens. Therefore, local storage of the countermeasures is preferable to ensure the greatest efficiency in combating the pathogens and to rapidly stop their spread. The best scenario could be achieved if local health professionals and emergency personal had convenient locally available supplies of vaccines that obviate the need for cold to ensure stability during storage. In the past few years, one of our two collaborating groups, the Group of Dr. Thomas Monath at Acambis has developed a new vaccine against Smallpox (Modified Vaccinia Ankara (MVA) and Japanese Encephalitis (ChimeriVax-JE live, attenuated chimeric vaccine). Both products are in clinical development under Food and Drug Administration (FDA) approved INDs. Both are live, attenuated vaccines and as such are susceptible to thermal degradation; hence, the vaccines must be kept refrigerated. During the past few years, the second of our two collaborating groups, Universal Stabilization Technologies (LIST), under the direction of Dr. Victor Bronshtein, has developed exciting new technologies for stabilizing bacteria and other live products. These technologies eliminate the damaging effects of conventional freeze-drying and allow the preparation of a live product that is stable at ambient temperature, eliminating the need for a cold chain. The objective of this grant proposal is to apply the novel technologies for stabilization developed at LIST to the manufacture of micronized ambient temperature stable MVA smallpox vaccine and ChimeriVax JE vaccine. Such formulated vaccines potentially could be delivered without need for reconstitution using transdermal, oral, nasal or inhalation delivery routes. During the first year our target will be vaccines that maintain high viability and potency after drying and subsequent storage at ambient temperatures. Working in collaboration, the Acambis and LIST will culture the vaccines, explore various ambient temperature stabilization approaches, confirm the stability and potency of the preserved vaccine, and test the immunogenicity and efficacy of the preserved vaccine using the mouse model.

描述（由申请人提供）：天花是20世纪上半叶全球发病和死亡的最重要原因之一。天花是一种潜在的生物恐怖主义媒介；它已被指定为A类优先病原体。尽管1980年宣布消灭天花，但由于天花库存的存在和生物恐怖主义的威胁，需要通过接种疫苗保持对天花的免疫力。近年来，蚊子传播的感染正在世界范围内以惊人的速度重新出现或出现。日本脑炎是生物恐怖主义的潜在病原体；它被指定为C类优先病原体。目前还没有获得许可的针对乙脑的抗病毒药物，针对天花的治疗方法也只有实验性的。因此，疫苗接种和病媒控制是唯一有效的预防工具，而疫苗接种是最具成本效益的战略。因此，对人民的有效保护需要立即采取针对这些病原体的对策。因此，最好在当地储存应对措施，以确保最大效率地防治病原体并迅速阻止其传播。如果当地保健专业人员和急救人员在当地有便利的疫苗供应，无需冷藏以确保储存期间的稳定性，则可以实现最佳情况。在过去几年中，我们的两个合作小组之一，Acambis的Thomas Monath博士小组开发了一种针对天花（改性安卡拉牛痘（MVA））和日本脑炎（chimerivax -乙脑减毒嵌合活疫苗）的新疫苗。这两种产品都在美国食品和药物管理局（FDA）批准的ind下进行临床开发。两者都是减毒活疫苗，因此容易热降解；因此，疫苗必须冷藏。在过去的几年里，我们两个合作小组中的第二个小组，通用稳定技术（LIST），在Victor Bronshtein博士的指导下，开发了令人兴奋的稳定细菌和其他活产品的新技术。这些技术消除了传统冷冻干燥的破坏性影响，并允许制备在环境温度下稳定的活产品，从而消除了冷链的需要。这项拨款提案的目的是将LIST开发的新型稳定技术应用于环境温度稳定的微细化MVA天花疫苗和ChimeriVax乙脑疫苗的生产。这种配方疫苗有可能通过透皮、口服、鼻腔或吸入等途径，在不需要重组的情况下进行递送。在第一年，我们的目标是在干燥和随后在环境温度下储存后保持高活力和效力的疫苗。Acambis和LIST将合作培养疫苗，探索各种环境温度稳定方法，确认保存疫苗的稳定性和效力，并使用小鼠模型测试保存疫苗的免疫原性和功效。